Shirakawa S, Kita K, Kobayashi T, Ohno T, Matsuoka N
Gan To Kagaku Ryoho. 1986 Sep;13(9):2734-44.
Malignant lymphoma is very heterogeneous in terms of its biological behavior. A strategy for the treatment of malignant lymphoma fundamentally requires a multidisciplinary field of treatment including mainly chemotherapy and radiotherapy in collaboration with surgical procedure and immunotherapy. The expressions of biological behavior such as histologic type, immunologic type, and stage of disease which influence the therapeutic effect and prognosis are actually very important in deciding a plan of treatment. Recent advances in chemotherapy have made it possible to cure advanced lymphoma patients, especially those with Hodgkin's disease. In this article the present state of treatment for malignant lymphoma is briefly reviewed from the viewpoint of its biological behavior.
恶性淋巴瘤在生物学行为方面具有很大的异质性。恶性淋巴瘤的治疗策略从根本上需要一个多学科的治疗领域,主要包括化疗和放疗,并与手术及免疫治疗协作。影响治疗效果和预后的生物学行为表现,如组织学类型、免疫类型和疾病分期,在制定治疗方案时实际上非常重要。化疗的最新进展已使治愈晚期淋巴瘤患者成为可能,尤其是霍奇金病患者。本文从恶性淋巴瘤生物学行为的角度简要综述了其治疗现状。